Treatment Profile of First‐Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End‐Stage Renal Disease on Dialysis
Toshio Takagi has received honoraria from Novartis, BMS, and Ono. Tsunenori Kondo has received honoraria from Pfizer, Novartis, BMS, and Ono. Toshio Takagi is an Editorial Board member of the International Journal of Urology and a co-authors of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication.
Authors
- Toshio Takagi (ORCID: https://orcid.org/0000-0003-1775-0943)
- Kazuhiko Yoshida (ORCID: https://orcid.org/0000-0002-3834-0153)
- Hiroki Ishihara (ORCID: https://orcid.org/0000-0002-5146-656X)
- Yuki Nemoto (ORCID: https://orcid.org/0000-0003-4290-0595)
- Tsunenori Kondo (ORCID: https://orcid.org/0000-0002-9130-0855)
- Shinsuke Mizoguchi
Institutions
- Kawaguchi Junior College (JP)
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
- Noguchi Hospital (JP)
- Heisei International University (JP)
Publication Details
- Journal
- International Journal of Urology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1111/iju.70320
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00